FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2010

Commission File Number: 000-33295

3SBIO INC.

(Translation of registrant’s name into English)

No. 3 A1, Road 10

Shenyang Economy & Technology Development Zone

Shenyang 110027

People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  x            Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):             

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨              No  x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- N/A

3SBio Inc. is furnishing under the cover of Form 6-K:

Exhibit 99.1 Press release, dated November 23, 2010, regarding that 3SBio Inc. announces results of Annual General Meeting.

Exhibit 99.2 Press release, dated November 29, 2010, regarding that 3SBio Inc. acquires worldwide rights to Pegsiticase from EnzymeRx.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

By: /s/ Dr. Jing Lou

Name:	Dr. Jing Lou
Title:	Chief Executive Officer

Date: December 10, 2010

EXHIBIT INDEX

Exhibit No.	Description
Exhibit 99.1	Press release, dated November 23, 2010, regarding that 3SBio Inc. announces results of Annual General Meeting
Exhibit 99.2	Press release, dated November 29, 2010, regarding that 3SBio Inc. acquires worldwide rights to Pegsiticase from EnzymeRx